SCHEMBL3106786

SCHEMBL3106786

CC(Oc1ccc2nc(NC(=O)NCCCN3CCN(Cc4c(F)cccc4Cl)CC3)sc2c1)c1c(Cl)ccc(F)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.43
DRD2 P14416 1/20 0.43
DRD3 P35462 1/20 0.43
ACHE P22303 1/20 0.42
CACNA1G O43497 2/20 0.42
ABL1 P00519 1/20 0.41
MET P08581 6/20 0.41
GHSR Q92847 3/20 0.41
KDR P35968 3/20 0.41
SRC P12931 2/20 0.41
KIT P10721 2/20 0.41
FGFR2 P21802 2/20 0.41
AXL P30530 2/20 0.41
FLT3 P36888 2/20 0.41
MST1R Q04912 2/20 0.41
AURKA O14965 1/20 0.40
LCK P06239 1/20 0.40
FYN P06241 1/20 0.40
IGF1R P08069 1/20 0.40
EPHA2 P29317 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3102523 0.90 MET (0.46) DRD2DRD3ABL1METGHSR
SCHEMBL3098640 0.90 MET (0.46) DRD2DRD3ABL1METGHSR
SCHEMBL3102114 0.88 MET (0.51) DRD2DRD3ABL1METGHSR
SCHEMBL3109350 0.88 ABL1 (0.48) ABL1METKDRSRCHCAR1
SCHEMBL3104505 0.87 ABL1 (0.53) DRD2DRD3ABL1METGHSR
SCHEMBL3102959 0.86 MET (0.51) ABL1METKDRSRCKIT
SCHEMBL3114877 0.85 MET (0.50) ABL1METKDRSRCKIT
SCHEMBL3650560 0.85 ABL1 (0.46) DRD2DRD3ABL1METKDR
SCHEMBL3094120 0.84 MET (0.55) ABL1MET
SCHEMBL3788533 0.84 ABL1 (0.54) ABL1METKDRSRCKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US claimed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US claimed
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
EP-2205568-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS Sanofi-Aventis (FR) 2010-07-14 EP disclosed
WO-2009087305-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS SANOFI-AVENTIS (FR) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 SIGMAR1 168/4885DRD2 955/4885DRD3 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.